Sign In
Buy VRTX
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
01:01pm, Friday, 19'th Apr 2024
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
Is Vertex Pharmaceuticals Stock a Millionaire Maker?
04:30am, Friday, 19'th Apr 2024
Vertex is growing beyond its highly successful cystic fibrosis business and into other areas of healthcare. The added growth opportunities should accelerate its growth rate, which slowed down last yea
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
08:30am, Thursday, 18'th Apr 2024
Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $4.9 billion. Alpine Immune Sciences' leading candidate looks highly promising.
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
07:06pm, Tuesday, 16'th Apr 2024
Vertex Pharmaceuticals (VRTX) closed at $394.17 in the latest trading session, marking a -0.8% move from the prior day.
Is Vertex (VRTX) a Buy as Wall Street Analysts Look Optimistic?
10:31am, Tuesday, 16'th Apr 2024
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
10:06am, Monday, 15'th Apr 2024
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
09:15am, Monday, 15'th Apr 2024
Vertex Pharmaceuticals is acquiring Alpine Immune Sciences. Alpine's lead asset could have a plurality of potential uses.
Could This Stock Be the Next Biotech Buyout?
05:29am, Saturday, 13'th Apr 2024
Vera Therapeutics is developing a dual-action antibody to treat kidney disorders, with successful results from the first portion of a pivotal study. Recently, Vertex Pharmaceuticals acquired Alpine Im
US biopharma first quarter earnings seen stable amid low expectations
11:47am, Friday, 12'th Apr 2024
Expectations for US biopharma companies' first quarter earnings are low given the typical seasonality across the sector and new healthcare plan signups, analysts at the Bank of America believe. “We
Vertex may have to pay more than $65 for Alpine Immune stock ($ALPN)
09:23am, Thursday, 11'th Apr 2024
Alpine Immune Sciences Inc (NASDAQ: ALPN) is up 35% on Thursday after Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said it will acquire the biotechnology company for $65 per share. Is Alpine Imm
Vertex Pharmaceuticals: Buy, Sell, or Hold?
09:15am, Thursday, 11'th Apr 2024
Vertex generated nearly $10 billion in sales last year from its cystic fibrosis drugs. However, the giant drugmaker has seen its growth rate slow from a year ago.
Vertex Pharma's $4.9 billion takeover of Alpine Immune expected to boost its rare-disease portfolio
08:06am, Thursday, 11'th Apr 2024
Vertex Pharmaceuticals Inc.'s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company's rare-disease franchise, analysts said Thursday.
Alpine Immune Sciences soars on $4.9bn Vertex takeover
07:16am, Thursday, 11'th Apr 2024
Alpine Immune Sciences Inc shares continued higher in pre-market trading, after soaring on Wednesday following news of the firm's US$4.9 billion takeover by Vertex Pharmaceuticals Incorporated. Shares
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch
10:45pm, Wednesday, 10'th Apr 2024
Vertex Pharmaceuticals (VRTX) will acquire clinical-stage immunotherapy company Alpine Immune Sciences (ALPN) in a deal valued at around $4.9 billion, both companies said Wednesday.
Vertex will buy Alpine Immune Sciences for $4.9B in another big Seattle biotech deal
08:16pm, Wednesday, 10'th Apr 2024
Boston-based biotech company Vertex Pharmaceuticals agreed to acquire Seattle-based Alpine Immune Sciences for $65 per share, totaling about $4.
